



Screen Type 1 Diabetes early, intervene sooner.

Type 1 Diabetes (T1D) affects millions worldwide, yet most cases aren't identified until irreversible beta-cell damage has occurred.

Early autoantibody screening identifies at-risk individuals, such as children, when interventions may still make a difference. Our IVDR-certified automated solution makes population-wide T1D screening accessible and actionable.

Why screen early?

Healthcare providers can identify children at risk before symptoms appear and intervene sooner:

- Prevent emergency diagnoses and diabetic ketoacidosis
- Enable access to emerging therapies and prevention trials
- Support informed healthcare planning for families and providers.

Fully automated autoantibody testing from dried blood spots.

Our multiplex assay harnesses the power of the GSP and the convenience of dried blood spot (DBS) cards to detect the three critical T1D autoantibodies: GAD65, IA-2, and ZnT8. One partner, one scalable solution.



Scalable: enables large-scale screening programs, with flexible processing options for different laboratory volumes



Reliable: built on proven newborn screening technology trusted in 115+ countries worldwide



Efficient: DBS collection eliminates cold chain requirements, simplifying sample logistics for population screening initiatives

Sample accessioning and punching by Panthera or DBS puncher

- 2 x 3.2 mm punches per sample
- Prepare up to 9 microtitration plates at once (Panthera)




Sample analysis by GSP

- Fully automatic from plate loading
- **Capacity:** 12 plates x 96 samples
- **Assay protocol:** 9 hours



Results reporting in GSP workstation

- GAD65/IA-2/ZnT8 combined positive/negative
- If positive, it should be confirmed with individual AAb tests*



*Available worldwide through Revvity Omics laboratory services (kit not available for purchase)

Introducing the GSP T1D 3plex kit



Target critical autoantibodies associated with insulin-producing beta cells with one multiplex kit. Our solution offers an efficient method for simultaneous quantitative detection of antibodies.

Antibodies tested:

- GAD65 (glutamic acid decarboxylase 65)
- IA-2 (islet antigen-2)
- ZnT8 (zinc transporter 8)



Contact us

Scan or click for more information

GSP T1D 3plex kit is a CE marked in vitro diagnostic medical device, compliant with IVD Regulation (EU) 2017/746, certified by Notified Body number 0537.
GSP and Panthera: CE marked in vitro diagnostic medical device, compliant with IVD Regulation (EU) 2017/746.
Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.

revvity